Navigation Links
ARIUS to Present at American Association for Cancer Research Annual,Meeting

- Lead Programs CD44 and Trop-2 poster Presentations Reveal New Findings -

TORONTO, April 4 - ARIUS Research Inc. (TSX: ARI), a biotechnology company discovering and developing the next wave of antibody therapeutics, today announced that new information on the preclinical activity of two of its novel monoclonal antibodies will be presented at the Annual Meeting of the American Association for Cancer Research (AACR), which runs from April 14-18, 2007 in Los Angeles, California. The first poster presentation will outline the activity of ARIUS' lead anti-CD44 antibody, ARH460-16-2, against liver cancer, a significant market in Asia and a growing concern in North America.

CD44 is an important marker for cancer stem cells that often survive treatment and keep growing to spread tumors. Studies of patients with different types of cancer have shown that CD44 can be linked to poorer chances of survival. ARIUS anti-CD44 antibodies have previously been found to control tumor growth and improve survival in breast and prostate cancer models.

The second poster will describe the activity of two antibodies targeting Trop-2 in a variety of solid tumors including breast and colon cancers plus pancreatic cancer, an area without effective treatment options. Trop-2 is a new target for drugs in cancer. Recently, increasing Trop-2 has been shown to
stimulate tumor growth. Studies in colon cancer patients found it is also associated with more aggressive disease and cancer death.

"Presenting our most recent findings for two of our lead programs, CD44 and Trop-2, is an excellent opportunity to showcase the potential of our products as we look for partners," said Dr. David Young, President and CEO. "Moreover, this important preclinical work also highlights the value and capabilities of our FunctionFIRST(TM) platform to generate novel antibodies with promising anti-cancer properties."

Novel antibody ARH460-16-2 rec
'"/>




Page: 1 2 3 4

Related medicine technology :

1. The Past, Present and Future of HLA Typing
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
5. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
6. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
10. Metabasis to Present at C.E. Unterberg, Towbin Emerging Growth Conference and Attend Pacific Growth Equities Conference
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference

Post Your Comments:
(Date:11/6/2009)... 6 Chimerix, Inc., a biopharmaceut...therapeutics to address life-threatening diseases,...ny,s lead antiviral compound, CMX001, to the World...ecurity Initiative (GHSI). CMX001 is a broad-spec...ment of smallpox, as well as other serious viral i...
(Date:11/6/2009)...NexBio Inc., in collaboration with scientists at t...), St. Louis University, and the University of Hon...icles in the peer-reviewed journal PLoS ONE. Thes...se ® ) may play a potentially important role ...nfluenza A(H1N1) and drug-resistant influenza. ,...
(Date:11/6/2009)... -- , - Trial Will Compare NXL103 With Le...lti-Resistant Staphylococcus Aureus (MRSA) Infecti...l company focused on the discovery and,development...nificant global,problem of microbial resistance, a...terial NXL103 (flopristin/linopristin), has starte...
Breaking Medicine Technology:Chimerix Updates the World Health Organization and the Global Health Security Initiative on Development of CMX001 as a Broad-Spectrum Therapeutic for Smallpox 2Chimerix Updates the World Health Organization and the Global Health Security Initiative on Development of CMX001 as a Broad-Spectrum Therapeutic for Smallpox 3NexBio(R) Publishes Two Articles Showing DAS181 (Fludase(R)*) Potently Inhibits Pandemic Influenza A(H1N1) and NAI-Resistant Influenza Viruses 2NexBio(R) Publishes Two Articles Showing DAS181 (Fludase(R)*) Potently Inhibits Pandemic Influenza A(H1N1) and NAI-Resistant Influenza Viruses 3NexBio(R) Publishes Two Articles Showing DAS181 (Fludase(R)*) Potently Inhibits Pandemic Influenza A(H1N1) and NAI-Resistant Influenza Viruses 4Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 2Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 3Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 4Exploring standards to advance microbial genomics 9201 1Exploring standards to advance microbial genomics 9201 2Exploring standards to advance microbial genomics 9201 3Abbott and Oasmia Pharmaceutical Announce Exclusive Distribution Agreement for Paccal 28R 29 Vet a New Chemotherapeutic Agent for Dogs 51323 1Abbott and Oasmia Pharmaceutical Announce Exclusive Distribution Agreement for Paccal 28R 29 Vet a New Chemotherapeutic Agent for Dogs 51323 2Abbott and Oasmia Pharmaceutical Announce Exclusive Distribution Agreement for Paccal 28R 29 Vet a New Chemotherapeutic Agent for Dogs 51323 3Abbott and Oasmia Pharmaceutical Announce Exclusive Distribution Agreement for Paccal 28R 29 Vet a New Chemotherapeutic Agent for Dogs 51323 4China Biotics Inc Announces Conference Call to Discuss Fourth Quarter and Full Year 2009 Financial Results 12968 1China Biotics Inc Announces Conference Call to Discuss Fourth Quarter and Full Year 2009 Financial Results 12968 2
...s; 11 Breast Cancer Studies; 9 Targeted,Agent Stud...all/ -- Lilly,Oncology will unveil 76 studies at t...Clinical Oncology (ASCO) in Chicago, Ill. from,Jun...ta on,GEMZAR(R) (gemcitabine HCl for injection), A...in, an investigational, oral, targeted,therapy. Th...
...ia--(BUSINESS WIRE)--May 23, 2007 -,ProtoKinetix I...studies conducted by ITTEC Stem, Inc. at the Unive...AAGP(TM) in the cryopreservation,process for stem ...ecule in the rapidly expanding stem cell industry....on human embryonic stem cells., Using standard cry...
Other Medicine Technology:Making Science Personal: Lilly Oncology to Unveil 76 Studies at,ASCO 2007 2ProtoKinetix's AAGP Dramatically Increases Recovery Rate of,Cryopreserved Stem Cells 2
(Date:11/8/2009)...he battle is won," said Dr. Charmaine Yoest. ,... a vote of 240-194, the Stupak-Ellsworth-Pitts-Kap...t abortion mandates and funding in HR 3962 passed ...e Action President and CEO Dr. Charmaine Yoest sai... the pro-life Americans across this country who ha...
(Date:11/8/2009)...e-USNewswire/ -- The following was released today ...recta Nex. ,, Mr. Terry and his associates fro...ild-killing by abortion out of any health care bil...reat first step to victory -- a touchdown in the f...d of us. Our rejoicing must be tempered by reality...
(Date:11/7/2009)...e-USNewswire/ -- Karen Ignagni, President and CEO ...ed the following statement today on House passage ... comprehensive health care reform, and we have con...e overhaul of how health insurance is provided. Ea...elimination of pre-existing condition exclusions, ...
(Date:11/7/2009)...-- Calling this a "defining moment" for the Americ... James Rohack, M.D., today addressed medical stude...al specialty societies at the opening of the AMA,s...ystem reform will top the agenda. ,, (Logo: h...O ) ,, "Over the next 72 hours, this AMA Hous...
(Date:11/7/2009)...e-USNewswire/ -- Speaker Nancy Pelosi and Democrat...n following a Democratic Whip meeting with Preside... Speaker,s opening remarks: ,, "Thank you very... us to receive the President of the United States ...r vote and making progress for the American people...
Breaking Medicine News(10 mins):Health News:Americans United for Life Action Comments on Passage of Pro-Life Amendment: Bipartisan Pro-life Majority Reflects the Will of the American People 2Health News:AHIP Statement on House Passage of H.R. 3962 2Health News:AMA President Kicks Off AMA Meeting Focused on Health Reform 2Health News:Pelosi Remarks Following House Democrats' Meeting with President Obama 2
...ity of implanted cardiac pacemakers and defibrilla... devices still tended to malfunction// at times. ...the pacemaker or the defibrillator reliability of ...a malfunctioning heart. Dr. William H. Maise...
... Nanaimo, B.C. man, George Cook father Cheryle Coo... be launched against the hospital. His death was m...treatment. It took seven hours before he was seen ...r's home to Nanaimo Regional General Hospital suff...
...ealed that women aged 60 and younger have an incre...tack compared to others. The results of the study ...th-care costs of such patients when compared to he...e. According to lead author Dr. Susmita Mallik...
... organization has undertaken a campaign to elimina... at the sixth International Multidisciplinary Cong...nital Infection and Neoplasia (EUROGIN) held in Pa... Government is a non-profit, bi-partisan organizat...
...a novel way to verify that the complete cancer has...ed report is published in the May issue of Radiolo...xplored region of the electromagnetic spectrum--th...ogy has the potential to eliminate the need for mu...
... survey it was found that pet owners are the main ...f human obesity pet obesity have propped up. //Acc...imals could cause as much suffering as those that ...oner about the number of obese pets that visited t...
Other Medicine News:Health News:Reliability of Pacemakers and Defibrillators to be Improved 2Health News:Depression Accompanies Heart Attacks in Younger Women 2Health News:Campaign to Eliminate Cervical Cancer 2Health News:Terahertz Imaging Promises To Revolutionize Breast Cancer Treatments 2
Chagatest ELISA
...with recombinant technology, that have been fully ...ble of detecting the different types of T.cruzi th...o acid sequences repeated in tandem. SAPA (shed ac... of the infection, it reacts with 93% of the patie...
T. cruzi IgG CELISA
Chagas Quick Step
Medicine Products: